RT Journal Article
SR Electronic
T1 Trio-based whole exome sequencing in patients with suspected sporadic inborn errors of immunity: a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.30.22272929
DO 10.1101/2022.03.30.22272929
A1 Hebert, Anne
A1 Simons, Annet
A1 Schuurs-Hoeijmakers, Janneke H.M.
A1 Koenen, Hans J.P.M.
A1 Zonneveld-Huijssoon, Evelien
A1 Henriet, Stefanie S.V.
A1 Schatorjé, Ellen J.H.
A1 Hoppenreijs, Esther P.A.H.
A1 Leenders, Erika K.S.M.
A1 Janssen, Etienne J.M.
A1 Santen, Gijs W.E.
A1 de Munnik, Sonja A.
A1 van Reijmersdal, Simon V.
A1 van Rijssen, Esther
A1 Kersten, Simone
A1 Netea, Mihai G.
A1 Smeets, Ruben L.
A1 van de Veerdonk, Frank L.
A1 Hoischen, Alexander
A1 van der Made, Caspar I.
YR 2022
UL http://medrxiv.org/content/early/2022/04/18/2022.03.30.22272929.abstract
AB Background De novo variants (DNVs) are currently not routinely evaluated as part of diagnostic whole exome sequencing (WES) analysis in patients with suspected inborn errors of immunity (IEI).Methods This study explored the potential added value of systematic assessment of DNVs in a retrospective cohort of 123 patients with a suspected sporadic IEI who underwent patient-parent trio-based WES.Results A likely molecular diagnosis for (part) of the immunological phenotype was achieved in 12 patients with the diagnostic in silico IEI WES gene panel. Exome-wide evaluation of rare, non-synonymous DNVs affecting coding or splice site regions led to the identification of 14 candidate DNVs in genes with an annotated immune function. DNVs were identified in IEI genes (NLRP3 and RELA) and potentially novel candidate genes, including PSMB10, DDX1, KMT2C and FBXW11. The FBXW11 canonical splice site DNV, in a patient with autoinflammatory disease, was shown to lead to defective RNA splicing, increased NF-κB p65 signalling, and elevated IL-1β production in primary immune cells.Conclusions This retrospective cohort study advocates the implementation of trio-based sequencing in routine diagnostics of patients with sporadic IEI. Furthermore, we have provided functional evidence supporting a causal role for FBXW11 loss-of-function mutations in autoinflammatory disease.Funding This research was supported by grants from the European Union, ZonMW and the Radboud Institute for Molecular Life Sciences.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors of this review acknowledge support from several funding parties. M. G. Netea was supported by an ERC Advanced Grant (No. 833247) and a Spinoza Grant of the Netherlands Organization for Scientific Support. This research was also part of a Radboud Institute for Molecular Life Sciences PhD grant (to M. G. Netea). F. L. van de Veerdonk was supported by a ZonMW Vidi grant and HDM-FUN EU H2020. A. Hoischen was supported by the Solve-RD project of the European Union's Horizon 2020 research and innovation programme (No. 779257).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients and their parents (encountered in Genome Diagnostics at the Department of Human Genetics in the Radboud University Medical Center (RUMC)) provided written informed consent for in silico IEI WES gene panel analysis with or without exome-wide variant analysis in line with the diagnostic procedure and clinical question, as approved by the local ethics committee (medisch-ethische toetsingscommissie Oost-Nederland). This research is in compliance with the principles of the Declaration of HelsinkiI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDNA sequencing data of patients are not publicly available as it is confidential human subject data. Data supporting the findings of this study are available within the article and its supplementary materials.